GENELUX CORP (GNLX)

GNLX Stock Earnings: Genelux Misses EPS for Q1 2024

GNLX stock results show that Genelux missed analyst estimates for earnings per share the first quarter of 2024.

GNLX Stock Earnings: Genelux Misses EPS for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Genelux (NASDAQ:GNLX) just reported results for the first quarter of 2024.Genel...

Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates

Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates

Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates...

Genelux Enters Oversold Territory (GNLX)

GNLX Stock Earnings: Genelux Misses EPS for Q4 2023

GNLX stock results show that Genelux missed analyst estimates for earnings per share the fourth quarter of 2023.

GNLX Stock Earnings: Genelux Misses EPS for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Genelux (NASDAQ:GNLX) just reported results for the fourth quarter of 2023.Gene...

Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update...

Genelux Becomes Oversold (GNLX)

Genelux files for a $300M mixed securities shelf (NASDAQ:GNLX)

Read about Genelux (GNLX)'s filing of a prospectus for a mixed shelf offering to raise up to $300M.

HC Wainwright starts Genelux at buy, cites Olvi-Vec potential (GNLX)

HC Wainwright initiated coverage of Genelux (GNLX) with a buy rating, highlighting the potential of its lead oncolytic virus Olvi-Vec in the treatment of tumors. Read more here.

Genelux gets fast track status for Olvi-Vec in ovarian cancer (GNLX)

Genelux (GNLX) has received fast-track status from the FDA for its Olvi-Vec program in the treatment of platinum resistant/refractory ovarian cancer. Read more here.

Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer

Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer

Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer...

Genelux is Now Oversold (GNLX)

Genelux Corporation Reports Third Quarter 2023 Financial Results and Provides General Business Updates

Genelux Corporation Reports Third Quarter 2023 Financial Results and Provides General Business Updates

- Expanded executive team as Lourie Zak appointed Chief Financial Officer -  - Extended clinical focus on systemic administration in small cell lung...

Friday Sector Laggards: Cigarettes & Tobacco, Biotechnology Stocks

Genelux 10% owner Aladar Szalay discloses sale of 5,704 shares (NASDAQ:GNLX)

Genelux Corporation (GNLX) 10% owner, Aladar Szalay, discloses the sale of 5,704 shares for $110,637, adding to previous insider trades.

Genelux Becomes Oversold (GNLX)

Genelux Corporation 10% owner discloses sale of 49,987 shares (NASDAQ:GNLX)

Genelux Corporation (GNLX) 10% owner, Aladar Szalay, sells nearly $1M worth of shares, as insider trading activity continues on the stock.

Young Adults and Pancreatic Cancer: What the 80% Rise in Diagnoses Means for Future Treatment

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GNLX),(NASDAQ:CRNX),(NYSE:PFE),(NASDAQ:SGEN) EQNX::TICKER_END

Genelux 10% owner continues to sell shares (NASDAQ:GNLX)

Genelux (GNLX) 10% owner Szalay Aladar continued to offload his stake in the biopharmaceutical company, with 75,690 shares sold at $25.4885 for total transactio

Genelux director continues to dispose of stake (NASDAQ:GNLX)

Genelux director continues to sell stake in biopharmaceutical company, with a total of 28 sells out of 34 insider trades in the past 3 months.

Genelux director disposes of stake (NASDAQ:GNLX)

Genelux (GNLX) stock falls as director Szalay Aladar sells off his direct and indirect stake in the company, disposing of 62,459 shares.

Genelux Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Genelux Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WESTLAKE VILLAGE, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today...